Medical Advocates
 

Kaletra Library Service 
 Conference Abstracts and Posters

Last Update:  December 08, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 

• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  A pilot study: lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) as dual agents in antiretroviral (ARV) naïve HIV-infected subjects
  (the LOREDA study)
  R. Andrade, E. Villarreal-Williams M. Mall
  Poster     Abstract
• POSTER
  Protease genotypes in children and adolescents failing protease inhibitor (PI) -based antiretroviral therapy (ART) at the
  Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana
  A. Gomila, B. Kirk, M. Tolle. et al
  Poster      Abstract
• POSTER
  Switching antiretroviral therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically
  suppressed HIV-infected patients is safe and well tolerated (the KITE study)
  I. Ofotokun, A.N. Sheth, K.A. Easley.
  Poster      Abstract
• POSTER
  Lopinavir/ritonavir-based HAART in HIV-1 naïve children: rare protease inhibitor resistance mutations but high 3TC/FTC resistance at the time of virologic failure
  P. Frange, S. Blanche, N. Briand, et al
  Poster      Abstract
• POSTER
  HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment: final results of a
  randomised, proof-of- principle clinical trial (KAMON 2 Study)
  H. Hasson, L. Galli, G. Gallotta
  Poster      Abstract
• POSTER
  No effect of HCV infection on virological response 96 weeks after simplification to lopinavir/ritonavir (LPV/r) monotherapy (MT) in the OK04 trial
  F. Pulido, J. Arribas, OK04 Study Group
  Poster      Abstract
• POSTER
  Minimal food effect on steady-state pharmacokinetics of lopinavir when administered as a tablet formulation in Ugandan HIV- positive patients
  M. Lamorde, P. Byakika-Kibwika, L. Nabukeera, et al
  Poster      Abstract
• Long term efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in
  Phnom Penh, Cambodia
  L. Ferradini, V. Ouk, O. Segeral, et al
  Abstract
• Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers
  R. Morgan, S. Campbell, K. Suehira, et al
  Abstract
• Bone mineral density (BMD) analysis in antiretroviral (ART)-naïve subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS study
  R. Qaqish, R. Trinh, M. Tian, et al
  Abstract
• Changes in bone mineral density after 96 weeks of treatment with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir in HIV-1 infected treatment naïve subjects: the CASTLE body composition sub-study
  G. Moyle, D. Ward, A. Farajallah. et al
  Abstract
• A comparative analysis of risk factors associated with efavirenz, darunavir/ritonavir, lopinavir/ritonavir, atazanavir/ritonavir and renal impairment
  N. Rockwood, M. Nelson, S. Mandalia, B. Gazzard
  Abstract
• Transplacental passage of nevirapine, nelfinavir and lopinavir
  S. van Hoog, K. Boer, J. Nellen
  Abstract

• HIV-1 drug resistance patterns in South Africans failing standardized treatment regimens: a comparison of adult vs. pediatric patients
  T. Rossouw, G. Malherbe, G. van Dyk, et al
  Abstract